Overview

To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin during SC Insulin Pump Therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Biodel

Treatments:

Insulin
Insulin Lispro
Insulin, Globin Zinc